Showing results (1-10 of 69) with videos related to
Sort By:
Pageof 7
Current Rheumatology Reports|January 26, 2015
Biosimilars: clinical interpretation and implications for drug developmentEduardo MyslerRheumatology (Oxford, England)|May 5, 2021
Phase III trials of JAK1 selective inhibitors in rheumatoid arthritisEduardo Mysler, Ana LizarragaExpert Opinion on Pharmacotherapy|June 10, 2020
Evaluating upadacitinib for the treatment of rheumatoid arthritisEduardo Mysler, Ana LizarragaOpen Access Rheumatology : Research and Reviews|June 9, 2021
Current and Emerging DMARDs for the Treatment of Rheumatoid ArthritisEduardo Mysler, Mariana Caubet, Ana LizarragaImmunotherapy|February 28, 2018
Etanercept for the treatment of rheumatoid arthritisSizheng Zhao, Eduardo Mysler, Robert J MootsCurrent Rheumatology Reports|August 11, 2018
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid ArthritisSizheng Zhao, Laura Chadwick, Eduardo Mysler, et al.Current Rheumatology Reports|November 10, 2018
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid ArthritisLaura Chadwick, Sizheng Zhao, Eduardo Mysler, et al.Rheumatology and Therapy|January 18, 2020
Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?Roy Fleischmann, Vipul Jairath, Eduardo Mysler, et al.Rheumatology International|July 7, 2009
Prevalence of positive ppd in a cohort of rheumatoid arthritis patientsMaria Natalia Tamborenea, Guillermo Tate, Eduardo Mysler, et al.Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|April 7, 2020
Subcutaneous Tocilizumab in Monotherapy or in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Latin American Patients With Moderate to Severe Active Rheumatoid Arthritis: A Multicenter, Phase IIIb StudyEduardo Mysler, Mario H Cardiel, Ricardo M Xavier, et al.Pageof 7